xcdkd | Knowledge4COVID-19

Property	Value
?:abstract	• Remdesivir is proposed as a therapeutic for COVID-19; • Clinical improvement after remdesivir was higher compared with placebo; • Remdesivir tended to reduce patient mortality rate, but this was not significant.
?:creator	<https://research.tib.eu/covid-19/entity/Enoki%2C_Yuki%3B_Igarashi%2C_Yuki%3B_Watabe%2C_Yuki%3B_Honma%2C_Kyoka%3B_Suzuki%2C_Yuto%3B_Hayashi%2C_Yukitaka%3B_Hiraoka%2C_Kana%3B_Taguchi%2C_Kazuaki%3B_Matsumoto%2C_Kazuaki>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.jgar.2020.11.022>
?:doi	10.1016/j.jgar.2020.11.022
?:journal	J_Glob_Antimicrob_Resist
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/2a8bdab48ee710a72996db41eee4ace16fd77008.json
?:pmc_json_files	document_parses/pmc_json/PMC7833743.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7833743>
?:pmid	<https://research.tib.eu/covid-19/entity/33307274.0>
?:pmid	33307274.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/783xcdkd_HAS_C4726677_TREATS_C5203670>
?:sha_id	<https://research.tib.eu/covid-19/entity/2a8bdab48ee710a72996db41eee4ace16fd77008>
?:source	Elsevier; Medline; PMC
?:title	Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-08

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/783xcdkd>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/783xcdkd>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all